Problems of Radiation Medicine and Radiobiology

D. O. Dzhuzha¹, S. D. Myasoyedov²

¹Nonprofit Organization National Cancer Institute of Ministry of Health of Ukraine, 33/43 Julia Zdanovska Str., Kyiv, 03022, Ukraine
²Shupyk National Healthcare University of Ministry of Health of Ukraine, 9 Dorogozhytska Str., Kyiv, 04112, Ukraine

RADIOPHARMACEUTICALS BASED ON FIBROBLAST ACTIVATION PROTEIN INHIBITORS IN ONCOLOGICAL PRACTICE

The review is devoted to the application of the new perspective class of radionuclide tracers, based on inhibitors of the fibroblast activation protein (FAP), which is a marker of cancer-associated fibroblasts of microenvironment of most malignant tumors. FAP inhibitors (FAPI) can be labeled by a wide spectrum of radionuclides, which can provide both radionuclide diagnostics and radionuclide therapy. It was showed, that the diagnostic efficacy of FAPI positron emission tomography/computed tomography (PET/CT) in various cancers is similar to 18F-fluorodesoxyglucose-PET/CT or superior. The FAPI radiopharmaceuticals (RP) have some advantage compared to 18F-fluorodesoxyglucose (FDG): no need for special preparation and diet, fast imaging with high contrast, and increased sensitivity in region with high glucose metabolism. FAPI-PET/CT may be an important addition to conventional methods in all stages of diagnostic process in oncology, especially when 18F-FDG cannot be used. It is need to further wide prospective investigations for assessing of diagnostic efficacy of FAPI-RP and determination of indications for its using.
Key words: fibroblast activation protein; radiolabeled fibroblast activation protein inhibitors; FAPI-PET/CT; radionuclide diagnostics; radionuclide therapy.

Problems of Radiation Medicine and Radiobiology.
2023;28:49-64. doi: 10.33145/2304-8336-2023-28-49-64

full text